Skip to main content
Clinical Trials/NCT02225210
NCT02225210
Unknown
Phase 4

Effects of Dexmedetomidine Sedation on Delirium and Haemodynamic in Mechanical Ventilated Elderly Patients -a Single Center,Randomized and Controlled Trial

Fuling Central Hospital of Chongqing City0 sites80 target enrollmentSeptember 2014

Overview

Phase
Phase 4
Intervention
Dexmedetomidine
Conditions
Safety of Dexmedetomidine Sedation
Sponsor
Fuling Central Hospital of Chongqing City
Enrollment
80
Primary Endpoint
The number of cases who develop delirium
Last Updated
11 years ago

Overview

Brief Summary

This study was designed to observe the effects of dexmedetomidine on delirium and haemodynamic in mechanical ventilated elderly patients,and to evaluate the safety of dexmedetomidine.

Registry
clinicaltrials.gov
Start Date
September 2014
End Date
July 2015
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fuling Central Hospital of Chongqing City
Responsible Party
Principal Investigator
Principal Investigator

Shuaiya

physician

Fuling Central Hospital of Chongqing City

Eligibility Criteria

Inclusion Criteria

  • Written informed consent
  • Intensive care unit patients who need mechanical ventilation
  • Anticipate duration of mechanical ventilation longer than 24 hours,and shorter than 96 hours prior to giving investigational products
  • Acute physiology and chronic health evaluation II score more than 10
  • Aged between 60 to 80 years old
  • Weight between plus or minus 20% of the standard weight. Male: (height cm - 80) × 70% = standard weight Female: (height cm - 70) × 60% = standard weight

Exclusion Criteria

  • Trauma and burn patients
  • Any kind of dialysis
  • Suspected or confirmed difficult airway
  • Use of neuromuscular blocking drugs(Except using for intubation )
  • Neuromuscular disease
  • Epidural or subarachnoid anesthesia
  • Plan to give general anesthesia before 24 hours drugs intervention or after giving investigational drugs
  • Serious central nervous system disease
  • Mental disability or mental disease
  • Acute hepatitis and serious liver disease(Child-Pugh C)

Arms & Interventions

Group dexmedetomidine ,dexmedetomidine

Continuous pump infusion dexmedetomidine with loading dose of 0.4μg.kg-1 for 10 minutes ,then followed by maintenance dose of 0.2\~0.7µg.kg-1 to maintain Sedation-Agitation Scale between 3 and 4.

Intervention: Dexmedetomidine

Group midazolam,midazolam,fentanyl

Quickly inject midazolam and fentanyl with loading dose of 0.1mg.kg-1 and 1 μg.kg-1 separately until attaining Sedation-Agitation Scale between 3 and 4,then followed by maintenance dose of 0.05\~0.1mg.kg-1.h-1 and fentanyl 0.5\~1μg.kg-1.h-1 separately.

Intervention: Midazolam

Group midazolam,midazolam,fentanyl

Quickly inject midazolam and fentanyl with loading dose of 0.1mg.kg-1 and 1 μg.kg-1 separately until attaining Sedation-Agitation Scale between 3 and 4,then followed by maintenance dose of 0.05\~0.1mg.kg-1.h-1 and fentanyl 0.5\~1μg.kg-1.h-1 separately.

Intervention: Fentanyl

Outcomes

Primary Outcomes

The number of cases who develop delirium

Time Frame: Within 48 hours after drug intervention

Changes in blood pressure within 48 hours after drug intervention

Time Frame: Within 48 hours after drug intervention

Number of Participants with blood pressure decrease more than 20% of the baseline value or systolic pressure less than 100 mmHg

Time Frame: within 48 hours afer drug intervention

Secondary Outcomes

  • Changes in heart rate(Within 48 hours after drug intervention)
  • Changes in respiratory rate(Within 48 hours after drug intervention)
  • Changes in central venous pressure(Within 48 hours after drug intervention)

Similar Trials